The Drug Discovery Informatics Market Size was surveyed at USD 2.96 billion out of 2022 and is supposed to addition to USD 7.08 billion by 2030, stretching out at a CAGR of 11.5% from 2023 to 2030.
A technology approach for evaluating and deciphering massive amounts of biological data is called drug discovery informatics. The information is gathered from clinical laboratory research experiments and is used to produce insights into the creation of various medications. Drug discovery informatics uses complex bioinformatics algorithms to process information about drugs, diseases, proteins, pathways, gene expression, and sequence data. It also extends the flexible architecture to build new, specialised approaches and algorithms for various aspects of drug discovery, which would help to lower the cost of drug development. Numerous hardware- and software-based tools are used for sequencing, target data processing, data visualization, docking, molecular modelling, and database security in the process of finding and developing new drugs. Because of this, it is commonly utilised by healthcare facilities, businesses involved in the pharmaceutical and biotechnology industries, and contract research organisations (CROs).
Get more information on Drug Discovery Informatics Market - Request Sample Report
DRIVERS
Increased investment in informatics research by the biotechnology and pharmaceutical sectors
Growing interest in, funding for, and demand for research into orphan drugs and uncommon diseases
Utilize informatics to concentrate on drug discovery
RESTRAINTS
Informatics software setup fees are very expensive
OPPORTUNITIES
Expired patents
expanding market for biologics and the biotechnology sector
expansion in emerging markets
CHALLENGES
Lack of qualified professionals
Countries' health systems have made significant investments in R&D to fight the COVID-19 virus during the current pandemic. Finding small molecule medications for COVID-19 treatment has been a focus of research teams around the world. The need for the drug discovery bioinformatics market therefore increases as a result of the ongoing pandemic and the increased drug development of medications. According to a study published in the journal Chemical Society Review with the title "A critical overview of computational approaches employed for COVID-19 drug discovery," a significant portion of research has been devoted to the identification of new drug candidates or the repurposing of already approved medications for COVID-19. According to the researcher, in order to find new drugs and drug combinations, computational tools must produce testable, experimentally actionable hypotheses. He also contends that open science and quick dissemination of research findings are essential for accelerating the development of novel, urgently needed COVID-19 therapeutics. As a result, the COVID-19 has a big impact on the market for drug discovery information.
By Workflow Type
Drug Discovery and Drug Development are two segments of the market. A substantial focus on the creation of precision pharmaceuticals caused the discovery informatics to dominate the industry. Personalized medical care is provided to patients based on their genetic and molecular profiles. Businesses offer discovery informatics solutions for utilising analytics for quick drug discovery, such PerkinElmer, Inc. The use of bioinformatics for quick medicine discovery is also being supported by the governments of numerous developing nations.
By Mode Type
Due to an increase in collaborations between pharmaceutical companies and contract development and manufacturing businesses, the category will continue to grow at a consistent CAGR during the projection period (CDMOs). Reports on novel drug entities are created by contract research organisations (CROs), which are then used by the sponsor or drug maker to submit to the U.S. FDA.
Partnering with a CRO that offers the same informatics solution as a pharmaceutical or biotechnology company has advantages. The CRO and the companies use a shared informatics platform to track study progress in a manner similar to how they track their own internal research. This aids the business in reducing costs and increasing productivity, which is anticipated to present the market's firms with a wealth of lucrative prospects.
By Service Type
With the fastest CAGR during the forecast period, the category will continue to hold the leading position. The creation of primary and secondary databases of nucleic acid, protein, and other biomolecule sequences makes extensive use of bioinformatic tools. The mining and storage of genome sequencing data are done using informatics tools in order to discover the genes and targeted proteins that will aid in the creation of prospective medications. Additionally, using various databases and sequence analysis tools like CLUSTALW, BLAST, and FASTA are necessary for doing fundamental drug discovery research. The introduction of novel and cutting-edge software is also a factor in the segment's expansion.
Users of the informatics platform can organize peptide sequences according to colour code and property. Due to its extensive use in the drug development process, molecular modelling is becoming more and more popular. These technologies are used to model and simulate biological systems and tiny molecules in order to comprehend and predict their molecular behavior. Additionally, they improve hit-to-lead optimization and hit discovery's cost-efficiency more quickly.
By Workflow Type
Discovery Informatics
Identification, Validation, & Assay Development Informatics
Lead Generation
Development Informatics
Lead Optimization
FHD Preparation
Phase IA
Phase IB/2
By Mode Type
Outsourced
In-house
By Service Type
Sequence Analysis Platforms
Docking
Clinical Trial Data Management
.png)
Need any customization research on Drug Discovery Informatics Market - Enquiry Now
There are four primary geographic divisions for the medication revelation informatics market: North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market for drug discovery informatics was dominated by North America, with Europe a close second. The presence of established CROs and increased R&D spending by pharmaceutical and biopharmaceutical businesses are two factors that contribute to North America's significant market share globally.
During the projected period, the CAGR for the Asia Pacific region is predicted to be the highest. Factors include the booming pharmaceutical and biopharmaceutical industries, the rise in CROs, and the lack of strict standards for drug discovery processes are all contributing factors.
REGIONAL COVERAGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Some of the major key players are as follows: Accenture, Boehringer Ingelheim International GmbH, Oracle, Certara, Agilent Technologies, Inc., Charles River, Infosys Ltd., Eurofins DiscoverX Products, Laboratories, Jubilant Biosys, Collaborative Drug Discovery, Inc., Selvita and Other Players.
| Report Attributes | Details |
|---|---|
| Market Size in 2022 | US$ 2.96 Billion |
| Market Size by 2030 | US$ 7.08 Billion |
| CAGR | CAGR of 11.5% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Workflow Type (Discovery Informatics (Identification, Validation, & Assay Development Informatics, Lead Generation), Development Informatics (Lead Optimization, FHD Preparation, Phase IA, Phase IB/2) • By Mode Type (Outsourced, In-house) • By Service Type (Sequence Analysis Platforms, Molecular Modeling, Docking, Clinical Trial Data Management) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Accenture, Boehringer Ingelheim International GmbH, Oracle, Certara, Agilent Technologies, Inc., Charles River, Infosys Ltd., Eurofins DiscoverX Products, Laboratories, Jubilant Biosys, Collaborative Drug Discovery, Inc., Selvita |
| DRIVERS | • Increased investment in informatics research by the biotechnology and pharmaceutical sectors • Growing interest in, funding for, and demand for research into orphan drugs and uncommon diseases • Utilize informatics to concentrate on drug discovery |
| RESTRAINTS | • Informatics software setup fees are very expensive |
Ans: The Drug Discovery Informatics market size was valued at US$ 2.96 billion in 2022.
Ans: The Drug Discovery Informatics Market is to grow at a CAGR of 11.5% over the forecast period 2023-2030.
Outsourced, and In-house are the sub segments of component of Drug Discovery Informatics market.
Drivers, Restraints, Opportunities, and Challenges are the factors of marketing dynamics Drug Discovery Informatics market.
The growing interest in, funding for, and demand for research into orphan drugs and uncommon diseases utilize informatics to concentrate on drug discovery are the key drivers of the Drug Discovery Informatics market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Drug Discovery Informatics Market Segmentation, By Workflow Type
8.1 Discovery Informatics
8.1.1 Identification, Validation, & Assay Development Informatics
8.1.2 Lead Generation
8.2 Development Informatics
8.2.1 Lead Optimization
8.2.2 FHD Preparation
8.2.3 Phase IA
8.2.4 Phase IB/2
9. Drug Discovery Informatics Market Segmentation, By Mode Type
9.1 Outsourced
9.2 In-house
10. Drug Discovery Informatics Market Segmentation, By Service Type
10.1 Sequence Analysis Platforms
10.2 Molecular Modeling
10.3 Docking
10.4 Clinical Trial Data Management
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 USA
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4 Asia-Pacific
11.4.1 Japan
11.4.2 South Korea
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.1 Israel
11.5.2 UAE
11.5.3 South Africa
11.5.4 Rest
11.6 Latin America
11.6.1 Brazil
11.6.2 Argentina
11.6.3 Rest of Latin America
12.Company Profiles
12.1 Accenture
12.1.1 Financial
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 Boehringer Ingelheim International GmbH
12.3 Oracle
12.4 Certara
12.5 Agilent Technologies, Inc.
12.6 Charles River
12.7 Infosys Ltd.
12.7 Eurofins DiscoverX Products
12.8 Laboratories
12.9 Jubilant Biosys
12.10 Collaborative Drug Discovery, Inc.
13. Competitive Landscape
13.1 Competitive Benchmark
13.2 Market Share Analysis
13.3 Recent Developments
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Nicotine Replacement Therapy Market size was valued at USD 3.13 Billion in 2023 and is expected to reach USD 4.49 Billion By 2031 and grow at a CAGR of 4.61% over the forecast period of 2024-2031.
The Cell Dissociation Market size was estimated USD 311.8 million in 2022 and is expected to reach USD 864.7 million by 2030 at a CAGR of 13.6% during the forecast period of 2023-2030.
The Intensive Care Unit (ICU) Market size was valued at $ 3.10 Bn in 2022 and is expected to reach $ 9.45 Bn by 2030,and grow at CAGR of 14.5 % over the forecast period of 2023-2030.
The Medical Swabs Market size was valued at USD 2.95 billion in 2022 and is expected to reach at USD 5.01 billion by 2030, and grow at a CAGR of 6.8% over the forecast period of 2023-2030
The Deep Brain Stimulation (DBS) Devices Market size was estimated USD 1.29 billion in 2023 and is expected to reach USD 2.78 billion By 2031 at a CAGR of 10% during the forecast period of 2024-2031.
The Wireless Brain Sensors Market Size was valued at USD 476.84 million in 2022, and is expected to reach USD 992.80 million by 2030, and grow at a CAGR of 9.6% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
